A Phase III, randomized, placebo-controlled, double-blind multicenter trial of RT-100 in patients with heart failure and reduced ejection fraction.

Trial Profile

A Phase III, randomized, placebo-controlled, double-blind multicenter trial of RT-100 in patients with heart failure and reduced ejection fraction.

Planning
Phase of Trial: Phase III

Latest Information Update: 14 Nov 2016

At a glance

  • Drugs RT 100 (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms FLOURISH
  • Most Recent Events

    • 14 Nov 2016 New trial record
    • 01 Nov 2016 According to a Renova Therapeutics media release, this trial will initiate in H2 2017. Company has submitted proposed trial protocol to FDA. Additional details on this trial, including patient enrollment information will be available next year 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top